Immunotherapy Research Antibodies

These antibodies specifically target clinically relevant proteins, including mouse homologs of current therapeutic targets that have been engineered for optimal in vivo performance, as well as bispecific antibodies, providing researchers with cutting-edge tools to propel cancer immunotherapy research forward.

Tools available to empower cancer immunotherapy research include:

• VivopureX™ Antibodies: These recombinant antibodies are engineered for improved in vivo performance in live mouse models, with Fc silencing and isotype switching for tailored therapeutic effects, and matched antibody species for reduced immunogenicity and longer serum half-life.
• Research-Grade Biosimilars: Absolute Antibody offers research-grade biosimilars to grant access to research tools for the study and evaluation of biological processes without the need to source and purchase costly therapeutic-grade biologics. The immunotherapy antibodies are engineered from the original human species into mouse, rabbit, rhesus monkey, and cynomolgus monkey formats for added research potential.
• Bispecific Antibodies: Engage two distinct targets with one antibody reagent with the range of recombinant engineered murine bispecific antibodies. The collection offers high purity, low immunogenicity, and tailored effector function for in vivo applications in mouse models. Absolute Antibody antibody engineers can also custom engineer any bispecific antibody you can imagine.
• Tumor Marker Antigens: Antibodies that target tumor markers can enhance cancer treatment and diagnosis. Benefit from the selection of recombinant engineered tumor marker antibodies, with 100% biological definition, Fc Silent™ formats for eliminated ADCC, and a variety of species and isotypes available to better address your research needs.